Friday, April 22, 2016 8:39:23 AM
As a scientist myself, I often see such schlock science presented by companies as proof that 'they have something' tangible (to sell to shareholders). So when I see something in the tech field that I can understand, it piques my interest and helps me identify whether the claims are likely bogus or not. Still not sure how the pro-enzyme works in the manner they claim. Most secreted proteins (all enzymes are proteins) are translated inside a cell in an 'immature' form, translated by ribosomes near/attached to the inside of the cell membrane. A leader/signal peptide at the beginning of the protein strand helps to get them through the cell membrane of the cells that produce them, then as the protein pops out the other side (outside) of the cell, then that segment of the N-terminus of the peptide is cleaved off to release and produce the mature protein or enzyme. Coming back the reverse way, not sure how pro-chymotrypsin or trypsin works, and how it works preferentially on cancer cells than any other cell? I'll have to read up. But I like the daily volume here.
------------------
Recent PPCB News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/31/2026 10:12:48 AM
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/19/2026 09:30:42 PM
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy • GlobeNewswire Inc. • 03/12/2026 12:45:00 PM
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study • GlobeNewswire Inc. • 03/10/2026 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/06/2026 10:22:19 PM
- Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors • IH Market News • 03/03/2026 03:34:06 PM
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models • GlobeNewswire Inc. • 03/03/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:19:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/25/2026 05:15:10 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/19/2026 10:28:16 PM
- Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results • GlobeNewswire Inc. • 02/18/2026 01:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 07:54:17 PM
- Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market • GlobeNewswire Inc. • 02/05/2026 01:45:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2026 10:29:59 PM
- Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations • GlobeNewswire Inc. • 01/27/2026 01:45:00 PM
- Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia • GlobeNewswire Inc. • 01/20/2026 01:45:00 PM
- Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer • GlobeNewswire Inc. • 01/15/2026 01:45:00 PM
- Propanc Biopharma Provides Shareholder Update • GlobeNewswire Inc. • 01/13/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 10:00:52 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/29/2025 10:13:52 PM
- Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal • GlobeNewswire Inc. • 12/22/2025 12:00:00 PM
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology • AllPennyStocks.com • 12/22/2025 11:45:00 AM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/10/2025 10:24:13 PM
